Swedish Orphan Biovitrum AB (Sobi™) today announced that Milan Zdravkovic has been appointed Senior Vice President, Head of Research & Development (R&D).
Milan joins Sobi from Novo Nordisk where he has had an 18 year tenure in the Research and Development organisation responsible for therapeutic areas including diabetes, growth hormone deficiency, obesity and immunology. Milan’s experience spans early stage development to post-approval life-cycle management in these areas. His most recent role was as Corporate Vice President, Obesity.
“We are delighted to welcome Milan to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Milan brings a creative global translational and development profile which can build and expand upon our strong legacy of biologics innovation.”
Milan will lead Sobi’s R&D efforts from post-proof of concept to late life cycle development, focusing on advancing and expanding Sobi’s early and mid-stage pipeline under a unified innovation strategy. “I am looking forward to joining the team at Sobi and to advancing Sobi’s mission to develop and deliver innovative therapies to people with rare diseases,” said Milan. Milan will join Sobi on 1 November 2016.
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.